Table 1:
Patient characteristics
| BMI <25* | BMI 25-30 | BMI ≥30 | p-value | |
|---|---|---|---|---|
| Total patients (n, %) | 87 (27.7) | 106 (33.8) | 121 (38.5) | - |
| Age at diagnosis (years, mean ± SD) | 59 ± 15 | 60 ± 14 | 59 ± 15 | 0.8 |
| Sex (Female, %) | 48 (55.2) | 47 (44.3) | 51 (42.5) | 0.1 |
| HCT co-morbidity index at diagnosis (mean ± SD) | 1.6 ± 2.1 | 1.7 ± 2 | 1.9 ± 2 | 0.03 |
| Comorbidities † | ||||
| • Coronary artery disease | 3 (3.4) | 9 (8.5) | 16 (13.2) | 0.04 |
| • Hypertension | 15 (17.2) | 33 (31.1) | 62 (51.2) | <0.0001 |
| Total bilirubin >1 mg/dl † | 19 (22.1) | 6 (5.8) | 27 (22.9) | 0.0005 |
| KPS at diagnosis | 84 ± 14 | 86 ± 10 | 86 ± 12 | 0.7 |
| WHO group at diagnosis (n, %) | 0.9 | |||
| • AML with recurrent genetic abnormalities | 17 (21.2) | 22 (22.2) | 23 (21.9) | |
| • AML with myelodysplasia related features | 21 (26.2) | 27 (27.3) | 28 (26.7) | |
| • Therapy related AML | 7 (8.8) | 6 (6.1) | 10 (9.5) | |
| • AML, NOS | 35 (43.8) | 44 (44.4) | 43 (41.9) | |
| Cytogenetic risk categories (n, %) | 0.9 | |||
| • Favorable | 9 (11.1) | 9 (8.6) | 10 (9.4) | |
| • Intermediate | 42 (51.9) | 61 (58.5) | 58 (54.7) | |
| • Adverse | 30 (37) | 35 (32.7) | 38 (35.9) | |
| FLT3 ITD mutation positive (n,%) | 13 (32.5) | 19 (40.4) | 14 (29.2) | 0.5 |
| NPM1 mutation positive (n,%) | 13 (48.1) | 11 (29.7) | 11 (30.6) | 0.2 |
| Initial chemotherapy (n,%) | 0.5 | |||
| • Intensive | 63 (72.4) | 71 (67) | 81 (66.9) | |
| • Low intensity | 16 (18.4) | 25 (23.6) | 33 (27.3) | |
| • None | 8 (9.2) | 10 (9.4) | 6 (5.8) | |
| Consolidation chemotherapy after remission (n, %) | 0.2 | |||
| • Intensive | 40 (81.6) | 40 (70.2) | 45 (81.8) | |
| • Low intensity | 0 (0) | 7 (12.3) | 2 (3.6) | |
| • None or unknown | 8 (16.3) | 9 (15.8) | 7 (12.7) |
*
One patient had BMI <18.5
†
Only comorbidities significantly difference among BMI groups are included.
AML- Acute myeloid leukemia, BMI- Body mass index, CR- Complete remission CRi- Complete remission with incomplete hematological response, HCT- Hematopoietic cell transplant, KPS- Karnofsky performance scale, NOS- Not otherwise specified, SD- Standard deviation, WHO- World Health Organization